Gülen DOĞUSOY, Süha GÖKSEL, Selda GÖÇENER, Haydar DURAK, Işıl PAKİŞ, Gökhan ERSOY

An immunohistohemical study of gastric neuroendocrine tumors: Expression of proliferating cell nuclear antigen and P53 oncoprotein

The aim of this study is to examine expression of Proliferating cell nuclear antigen (PCNA) and p53 oncoprotein in gastric neuroendocrine tumors. 35 gastric neuroendocrine tumors were analyzed for first histopathologic features and then, immunohistochemical study was done to detect labeling index of PCNA and accumulation of p53 protein by using monoclonal antibodies and the Labeled strepavidin-biotin method. PCNA labeling index and p53 protein expression were compared with histopatholoic features in statistical methods of Fisher's exact, chi square and logistic regression tests. No significant correlation was found between them except PCNA score and depth of invasion. In conclusion, our findings show that not p53 but PCNA appears to be useful in detecting malignant potential of these tumors.

PDF

___

1. Klöppel G., Heitz Pu., Capella C., Solcia E.: Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World, Surg 20: 132-141, 1996.
2. Capella C, Heitz PU, Pöfler H, Solcia E, Klöppel G. Resived classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 55 (Suppl 3): 11-23, 1994.
3. Rindi G.: Clinicopathologic aspects of gastric neuroendocrine tumors. Am J Surg Pathol 19 (Suppl 1): S20-S29, 1995.
4. Rind iG., Bordi C., Rappel S., La Rosa., Stolte M., Solcia E.: Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 20: 168-172, 1996.
5. Maeda K, Chung Y, Onoda N, Kato Y, Nitta A, Arimoto Y, Yamada N, Kondo Y, Sowa M. Proliferating cell nuclear antigen labeling index o f preoperative biopsy specimens in gastric carcinoma with special reference to prognosis. Cancer 73; 528-533, 1994.
6. Wright PA, Quirke P, Attanoos R, Williams GT. Molecular pathology of gastric carcinoma: Progress and prospects. Hum Pathol 23: 848-859, 1992.
7. Stemmermann G, Heffelfinger SC, Noffsinger A, Hui YZ, Miller MA, Fenoglio-Preiser CM. The molecular biology of esophageal and gastric cancer and their precursors: Oncogenes, tumor suppressor genes, and growth factors. Hum Pathol 25: 968-981, 1994.
8. Hurlimann J, Saraga EP. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis. Am J Pathol 18(12): 1247- 1253, 1994.
9. Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 24: 584- 589, 1993.
10. Fukunaga M, Monden T, Nakanishi H, Ohue M, Fukuda K, Tomita N, Shimano T, Mori T. Immunohistochemical study of p53 in gastric carcinoma. Am J Clin Pathol 101: 177-180, 1994.
11. Martin IG, Scott NS, Bell S, Pickles A, Murday V, Dixon MF, Johnston D, Quirke P. Gastric cancer is not associated with Ki ras mutations or abnormal p53 expression. Gut 31: A1178, 1990.
12. Guesdon JL, Ternyn CKT, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic tecniques. J. Histochem. Cytochem. 27; 1131- 1139, 1979.
13. Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76: 720-726, 1995.
14. Ooi A, Hayashi H, Katsuda S, Nakanishi I. Gastric carcinoma cells with endocrine differentiation show no evidence of poliferation. Hum Pathol 23: 736-741, 1992.
15. Wang DG, Johnston CF, Buchanan KD. Oncogene expression in gastroenteropancreatic neuroendocrine tumors. Cancer 80: 668-75, 1997.
16. Maehara Y, Tomisaki S, Oda S, et al. Lymph node metastasis and relation to tumor growth potential and local immun response in advanced gastric cancer. Int J Cancer 74(2): 224-228, 1997.
17. Iochim E, Goussia A, Stefanou D, Agnantis NJ. Expession of p53 protein in gastric cancer: an immunohistochemical study with correlation to proliferative activity. Anticancer Res. 17(1A): 513-517, 1997.
18. Wu MS, Shun CT, Wang HP, Sheu JC, Lee WJ, Wang TH, Lin JT. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 112: 1457-1465, 1997.
19. Vollmers HP, Dammrich J, Hensel F, Ribbert H, Meyer-Bahlburg A, UfkenGaul T, Korff M, Müller -Hermelink HK. Differentiated expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer 79: 433- 40, 1997.
20. Shun CT, Wu MS, Lin JT, et al. Relationship of p53 and c-erbB-2 expression to histopathological features, helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 44(14): 604- 609, 1997.
21. Ichiyoshi Y, Tomoda M, Tomisaki S, et al. Macroscopic appearance and biological character of gastric cancer invading the muscularis propria. Hepatogastroenterology 43(9): 553- 559, 1996.
22. Ichiyoshi Y, Oiwa H, Tomisaki S, et al. Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. Hepatogastroenterology 44(14): 546- 553, 1997.
23. Kanai T, Konno H, Maruyama K, et al. P53 overexpression and proliferative activity do not correlate with lymph node metastasis in early gastric cancer. Eur Surg Res 29(1): 35-41, 1997.
24. Kim JH, Uhm HD, Gong SJ, et al. Relationship between p53 overexpression and gastric cancer progression. Oncology 54(2): 166- 170, 1997.
25. Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 79: 2067- 2072, 1997.